Omega Diagnostics Group PLC Exercise of Options and Total Voting Rights (8780P)
05 September 2017 - 11:07PM
UK Regulatory
TIDMODX
RNS Number : 8780P
Omega Diagnostics Group PLC
05 September 2017
5 September 2017
Omega Diagnostics Group PLC
("Omega" or the "Company")
Exercise of Options and Total Voting Rights
Omega (AIM: ODX), the medical diagnostics company focused on
allergy, food intolerance and infectious disease, announces that it
has allotted 75,000 new ordinary shares of 4 pence each in the
capital of the Company ("Ordinary Shares") following the exercise
of share options by an employee.
Application has been made to the London Stock Exchange for the
75,000 new Ordinary Shares to be admitted to trading on AIM
("Admission") and it is expected that Admission will become
effective and trading will commence at 8.00 a.m. on 11 September
2017.
After Admission, the total number of Ordinary Shares in issue
will be 126,959,060 and the total number of voting rights will
therefore be 126,959,060. This figure may be used by shareholders
as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a
change to their interest in, the share capital of the Company under
the FCA's Disclosure and Transparency Rules.
Contacts:
Omega Diagnostics Group Tel: 01259 763 030
PLC
Andrew Shepherd, Chief Executive
Kieron Harbinson, Group www.omegadiagnostics.com
Finance Director
Jag Grewal, Group Sales
and Marketing Director
finnCap Ltd Tel: 020 7220 0500
Geoff Nash/James Thompson
(Corporate Finance)
Mia Gardner (Corporate Broking)
Walbrook PR Limited Tel: 020 7933 8780 or omega@walbrookpr.com
Paul McManus Mob: 07980 541 893
Lianne Cawthorne Mob: 07584 391 303
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOESSIFDIFWSESU
(END) Dow Jones Newswires
September 05, 2017 09:07 ET (13:07 GMT)
Omega Diagnostics (LSE:ODX)
Historical Stock Chart
From Apr 2024 to May 2024
Omega Diagnostics (LSE:ODX)
Historical Stock Chart
From May 2023 to May 2024